Financial Analysis: Civitas Solutions (CIVI) vs. Its Rivals

Civitas Solutions (NYSE: CIVI) is one of 127 publicly-traded companies in the “MEDICAL CARE” industry, but how does it weigh in compared to its rivals? We will compare Civitas Solutions to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares Civitas Solutions and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Civitas Solutions $1.47 billion $6.33 million 48.23
Civitas Solutions Competitors $7.60 billion $240.26 million -13,317.87

Civitas Solutions’ rivals have higher revenue and earnings than Civitas Solutions. Civitas Solutions is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Civitas Solutions and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Civitas Solutions 0.76% 19.77% 3.08%
Civitas Solutions Competitors -68.28% -652.99% -22.79%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Civitas Solutions and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Civitas Solutions 0 0 5 0 3.00
Civitas Solutions Competitors 719 3453 5307 128 2.50

Civitas Solutions currently has a consensus price target of $20.00, indicating a potential upside of 33.78%. As a group, “MEDICAL CARE” companies have a potential upside of 9.98%. Given Civitas Solutions’ stronger consensus rating and higher probable upside, analysts plainly believe Civitas Solutions is more favorable than its rivals.

Institutional & Insider Ownership

94.6% of Civitas Solutions shares are owned by institutional investors. Comparatively, 59.7% of shares of all “MEDICAL CARE” companies are owned by institutional investors. 5.3% of Civitas Solutions shares are owned by insiders. Comparatively, 16.6% of shares of all “MEDICAL CARE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Civitas Solutions has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Civitas Solutions’ rivals have a beta of 1.25, indicating that their average share price is 25% more volatile than the S&P 500.

Summary

Civitas Solutions beats its rivals on 8 of the 13 factors compared.

About Civitas Solutions

Civitas Solutions, Inc. is a provider of home- and community-based health and human services to individuals with intellectual, developmental, physical or behavioral disabilities and other special needs. The Company operates through two segments: Human Services and Post-Acute Specialty Rehabilitation Services (SRS). The Human Services segment provides home- and community-based human services to individuals with intellectual and/or developmental disabilities (I/DD), youth with emotional, behavioral and/or medically complex challenges or at-risk youth (ARY), and elders. The SRS segment delivers healthcare and community-based health and human services to individuals having suffered acquired brain injury, spinal injuries, and other catastrophic injuries and illnesses. Within its SRS segment, its NeuroRestorative business unit is focused on rehabilitation and transitional living services, and its CareMeridian business unit is focused on the medically-intensive post-acute care services.

Receive News & Ratings for Civitas Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Civitas Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Insider Selling: New Relic  Insider Sells 4,000 Shares of Stock
Insider Selling: New Relic Insider Sells 4,000 Shares of Stock
Qualified Master Fund L. Abdiel Acquires 12,584 Shares of Appian  Stock
Qualified Master Fund L. Abdiel Acquires 12,584 Shares of Appian Stock
Timken  Expected to Post Quarterly Sales of $834.83 Million
Timken Expected to Post Quarterly Sales of $834.83 Million
Insider Selling: TechTarget  Director Sells $363,903.96 in Stock
Insider Selling: TechTarget Director Sells $363,903.96 in Stock
City Of London Investment Grou Purchases 24,200 Shares of Morgan Stanley Emerging Market  Stock
City Of London Investment Grou Purchases 24,200 Shares of Morgan Stanley Emerging Market Stock
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect 3D Systems  Share Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect 3D Systems Share Price


© 2006-2018 Ticker Report. Google+.